Fusion Antibodies PLC
05 October 2026
REACH- non-regulatory announcement
5 October 2026
Fusion Antibodies plc
("Fusion" or the "Company")
Launch of new customer-focused website
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the launch of its new customer-focused website.
The redesigned website provides an updated presentation of Fusion’s antibody discovery, engineering and supply capabilities and is intended to make it easier for existing and prospective customers to understand the Company’s range of services and proprietary technologies, including its library-based discovery platforms.
The website remains available at www.fusionantibodies.com.
Enquiries:
|
Investor questions on this announcement |
|
|
|
We encourage all investors to share questions on this announcement via our investor hub |
||
|
|
|
|
|
Fusion Antibodies plc |
||
|
Adrian Kinkaid, Chief Executive Officer Stephen Smyth, Chief Financial Officer |
Via Walbrook PR |
|
|
|
|
|
|
Allenby Capital Limited |
Tel: +44 (0) 20 3328 5656 |
|
|
James Reeve/Vivek Bhardwaj (Corporate Finance) Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking) |
|
|
|
|
|
|
|
|
|
|
|
Shard Capital Partners LLP |
|
|
|
Damon Heath (Joint Broker) |
Tel: +44 (0) 207 186 9952 |
|
|
|
|
|
|
|
|
|
|
Walbrook PR |
Tel: +44 (0)20 7933 8780 orfusion@walbrookpr.com |
|
|
Anna Dunphy |
Mob: +44 (0)7876 741 001 |
|
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRxTM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen’s University Belfast. The Company’s mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.
Fusion Antibodies’ growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable pharmaceutical and biotechnology companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.
About Reach announcements
This is a Reach announcement. Reach is aninvestor communication service aimed at assisting listed and unlisted (including AIM quoted) companies todistributemedia only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.